3/4
04:05 pm
lrmr
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Medium
Report
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
3/4
08:57 am
lrmr
Larimar Therapeutics price target raised to $12 from $11 at Wedbush [Yahoo! Finance]
Low
Report
Larimar Therapeutics price target raised to $12 from $11 at Wedbush [Yahoo! Finance]
3/3
10:18 am
lrmr
Larimar Therapeutics (LRMR) had its price target raised by Wedbush from $11.00 to $12.00. They now have an "outperform" rating on the stock.
Low
Report
Larimar Therapeutics (LRMR) had its price target raised by Wedbush from $11.00 to $12.00. They now have an "outperform" rating on the stock.
2/28
11:22 am
lrmr
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? [Yahoo! Finance]
2/25
08:59 pm
lrmr
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Medium
Report
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
2/25
04:01 pm
lrmr
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
Low
Report
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
2/25
02:34 pm
lrmr
Larimar Therapeutics (LRMR) had its price target raised by Citigroup Inc. from $12.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
Larimar Therapeutics (LRMR) had its price target raised by Citigroup Inc. from $12.00 to $14.00. They now have a "buy" rating on the stock.
2/25
08:22 am
lrmr
Larimar Therapeutics (LRMR) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
High
Report
Larimar Therapeutics (LRMR) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
2/25
06:24 am
lrmr
Larimar Therapeutics (LRMR) was upgraded by Lifesci Capital to "strong-buy".
High
Report
Larimar Therapeutics (LRMR) was upgraded by Lifesci Capital to "strong-buy".
2/24
09:32 am
lrmr
Larimar Therapeutics' Friedreich's Ataxia Therapy Receives FDA Breakthrough Status; Shares Rise [Yahoo! Finance]
Low
Report
Larimar Therapeutics' Friedreich's Ataxia Therapy Receives FDA Breakthrough Status; Shares Rise [Yahoo! Finance]
2/24
07:00 am
lrmr
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
High
Report
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
1/7
07:11 am
lrmr
Larimar Therapeutics (NASDAQ:LRMR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Larimar Therapeutics (NASDAQ:LRMR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
12/18
08:00 am
lrmr
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference